Mast cells granular contents are crucial for deep vein thrombosis in mice

Circulation Research

Volumn 121, Issue 8, 2017, Pages 941-950

  Ponomaryov, Tatyana ^a   Payne, Holly ^a   Fabritz, Larissa ^a,b   Wagner, Denisa D ^c,d   Brill, Alexander ^a,c,d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Endothelium; Histamine; Mast cells; Venous thrombosis

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; VON WILLEBRAND FACTOR; FIBRINOLYTIC AGENT; HISTAMINE; ICAM1 PROTEIN, HUMAN; SELENOPROTEIN P; STEM CELL FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; IN VITRO STUDY; INFERIOR CAVA VEIN; MAST CELL; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SECRETORY GRANULE; THROMBOSIS PREVENTION; UMBILICAL VEIN ENDOTHELIAL CELL; VALIDATION PROCESS; WEIBEL PALADE BODY SECRETAGOGUE; WILD TYPE MOUSE; ADOPTIVE TRANSFER; ANIMAL; BLOOD; BLOOD CLOTTING; C57BL MOUSE; CELL CULTURE; DEFICIENCY; DEGRANULATION; DISEASE MODEL; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; HUMAN; KNOCKOUT MOUSE; LIGATION; METABOLISM; PHENOTYPE; SIGNAL TRANSDUCTION; SURGERY; THROMBOCYTE; TRANSPLANTATION; VENOUS THROMBOSIS; WEIBEL PALADE BODY;

ADOPTIVE TRANSFER; ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; CELL DEGRANULATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; GENETIC PREDISPOSITION TO DISEASE; HISTAMINE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LIGATION; MAST CELLS; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-KIT; SELENOPROTEIN P; SIGNAL TRANSDUCTION; VENA CAVA, INFERIOR; VENOUS THROMBOSIS; VON WILLEBRAND FACTOR; WEIBEL-PALADE BODIES;

EID: 85026235438     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.311185     Document Type: Article

References (53)

1. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41:3–14. doi: 10.1007/s11239-015-1311-6.
2. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585–593.
3. Becattini C, Agnelli G, Lankeit M, Masotti L, Pruszczyk P, Casazza F, Vanni S, Nitti C, Kamphuisen P, Vedovati MC, De Natale MG, Konstantinides S. Acute pulmonary embolism: mortality prediction by the 2014 european society of cardiology risk stratification model. Eur Respir J. 2016;48:780–786. doi: 10.1183/13993003.00024-2016.
4. Office of the Surgeon General (US). The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. National Heart, Lung, and Blood Institute. Rockville, MD; 2008.
5. Thom T, Haase N, Rosamond W, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–e151. doi: 10.1161/CIRCULATIONAHA.105.171600.
6. Ashrani AA, Heit JA. Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis. 2009;28:465–476. doi: 10.1007/s11239-009-0309-3.
7. Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, Goldsmith K, Coghlan JG, Pepke-Zaba J. Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33:332–338. doi: 10.1183/09031936.00092008.
8. Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol. 2010;56:1–7. doi: 10.1016/j.jacc.2010.01.057.
9. Enga KF, Rye-Holmboe I, Hald EM, Løchen ML, Mathiesen EB, Njølstad I, Wilsgaard T, Braekkan SK, Hansen JB. Atrial fibrillation and future risk of venous thromboembolism: the Tromsø study. J Thromb Haemost. 2015;13:10–16. doi: 10.1111/jth.12762.
10. Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol. 1974;27:517–528.
11. Bovill EG, van der Vliet A. Venous valvular stasis-associated hypoxia and thrombosis: what is the link? Annu Rev Physiol. 2011;73:527–545. doi: 10.1146/annurev-physiol-012110-142305.
12. Hamer JD, Malone PC, Silver IA. The PO2 in venous valve pockets: its possible bearing on thrombogenesis. Br J Surg. 1981;68:166–170.
13. Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Köllnberger M, Wakefield TW, Lämmle B, Massberg S, Wagner DD. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011;117:1400–1407. doi: 10.1182/blood-2010-05-287623.
14. Myers DD, Wakefield TW. Inflammation-dependent thrombosis. Front Biosci. 2005;10:2750–2757.
15. Reitsma PH, Versteeg HH, Middeldorp S. Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol. 2012;32:563–568. doi: 10.1161/ATVBAHA.111.242818.
16. Brill A, Fuchs TA, Savchenko AS, Thomas GM, Martinod K, De Meyer SF, Bhandari AA, Wagner DD. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012;10:136–144. doi: 10.1111/j.1538-7836.2011.04544.x.
17. von Brühl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209:819–835. doi: 10.1084/jem.20112322.
18. Gurish MF, Austen KF. Developmental origin and functional specialization of mast cell subsets. Immunity. 2012;37:25–33. doi: 10.1016/j.immuni.2012.07.003.
19. Lippi G, Favaloro EJ. Allergy and venous thromboembolism: a casual or causative association. Semin Thromb Hemost. 2016;42:63–68. doi: 10.1055/s-0035-1568876.
20. Modena BD, Dazy K, White AA. Emerging concepts: mast cell involvement in allergic diseases. Transl Res. 2016;174:98–121. doi: 10.1016/j.trsl.2016.02.011.
21. Voehringer D. Protective and pathological roles of mast cells and baso-phils. Nat Rev Immunol. 2013;13:362–375. doi: 10.1038/nri3427.
22. Sillaber C, Baghestanian M, Bevec D, Willheim M, Agis H, Kapiotis S, Füreder W, Bankl HC, Kiener HP, Speiser W, Binder BR, Lechner K, Valent P. The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. J Immunol. 1999;162:1032–1041.
23. Kunder CA, St John AL, Abraham SN. Mast cell modulation of the vascular and lymphatic endothelium. Blood. 2011;118:5383–5393. doi: 10.1182/blood-2011-07-358432.
24. Bankl HC, Grossschmidt K, Pikula B, Bankl H, Lechner K, Valent P. Mast cells are augmented in deep vein thrombosis and express a profibrinolytic phenotype. Hum Pathol. 1999;30:188–194.
25. Nocka K, Tan JC, Chiu E, Chu TY, Ray P, Traktman P, Besmer P. Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W37, Wv, W41 and W. EMBO J. 1990;9:1805–1813.
26. Lyon MF, Glenister PH. A new allele sash (Wsh) at the W-locus and a spontaneous recessive lethal in mice. Genet Res. 1982;39:315–322.
27. Stevens J, Loutit JF. Mast cells in spotted mutant mice (W Ph mi). Proc R Soc Lond B Biol Sci. 1982;215:405–409.
28. Geddings J, Aleman MM, Wolberg A, von Brühl ML, Massberg S, Mackman N. Strengths and weaknesses of a new mouse model of thrombosis induced by inferior vena cava stenosis: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:571–573. doi: 10.1111/jth.12510.
29. Shelburne CP, McLachlan JB, Abraham SN. In vivo models for studying mast cell-dependent responses to bacterial infection. Methods Mol Biol. 2006;315:363–381.
30. Kuehn HS, Radinger M, Gilfillan AM. Measuring mast cell mediator release. Curr Protoc Immunol. 2010;Chapter 7:Unit7.38. doi: 10.1002/0471142735.im0738s91.
31. Carvalho M, Benjamim C, Santos F, Ferreira S, Cunha F. Effect of mast cells depletion on the failure of neutrophil migration during sepsis. Eur J Pharmacol. 2005;525:161–169. doi: 10.1016/j.ejphar.2005.09.049.
32. Ramos L, Peña G, Cai B, Deitch EA, Ulloa L. Mast cell stabilization improves survival by preventing apoptosis in sepsis. J Immunol. 2010;185:709–716. doi: 10.4049/jimmunol.1000273.
33. Bot I, de Jager SC, Zernecke A, Lindstedt KA, van Berkel TJ, Weber C, Biessen EA. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation. 2007;115:2516–2525. doi: 10.1161/CIRCULATIONAHA.106.660472.
34. Fabritz L, Hoogendijk MG, Scicluna BP, et al. Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. J Am Coll Cardiol. 2011;57:740–750. doi: 10.1016/j.jacc.2010.09.046.
35. Sabrane K, Kruse MN, Fabritz L, Zetsche B, Mitko D, Skryabin BV, Zwiener M, Baba HA, Yanagisawa M, Kuhn M. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest. 2005;115:1666–1674. doi: 10.1172/JCI23360.
36. Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106:385–392. doi: 10.1172/JCI9896.
37. Wolters PJ, Mallen-St Clair J, Lewis CC, Villalta SA, Baluk P, Erle DJ, Caughey GH. Tissue-selective mast cell reconstitution and differential lung gene expression in mast cell-deficient Kit(W-sh)/Kit(W-sh) sash mice. Clin Exp Allergy. 2005;35:82–88. doi: 10.1111/j.1365-2222.2005.02136.x.
38. Furuta T, Kikuchi T, Iwakura Y, Watanabe N. Protective roles of mast cells and mast cell-derived TNF in murine malaria. J Immunol. 2006;177:3294–3302.
39. Antonopoulos CN, Sfyroeras GS, Kakisis JD, Moulakakis KG, Liapis CD. The role of soluble P selectin in the diagnosis of venous thromboembolism. Thromb Res. 2014;133:17–24. doi: 10.1016/j.thromres.2013.08.014.
40. Vandy FC, Stabler C, Eliassen AM, Hawley AE, Guire KE, Myers DD, Henke PK, Wakefield TW. Soluble P-selectin for the diagnosis of lower extremity deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2013;1:117–1125. doi: 10.1016/j.jvsv.2012.09.001.
41. Culmer DL, Diaz JA, Hawley AE, Jackson TO, Shuster KA, Sigler RE, Wakefield TW, Myers DD, Jr. Circulating and vein wall P-selectin promote venous thrombogenesis during aging in a rodent model. Thromb Res. 2013;131:42–48. doi: 10.1016/j.thromres.2012.10.013.
42. Ramacciotti E, Blackburn S, Hawley AE, Vandy F, Ballard-Lipka N, Stabler C, Baker N, Guire KE, Rectenwald JE, Henke PK, Myers DD, Jr, Wakefield TW. Evaluation of soluble P-selectin as a marker for the diagnosis of deep venous thrombosis. Clin Appl Thromb Hemost. 2011;17:425–431. doi: 10.1177/1076029611405032.
43. Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, Schunack W, Levi R, Haas HL. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev. 1997;49:253–278.
44. Li H, Burkhardt C, Heinrich UR, Brausch I, Xia N, Förstermann U. Histamine upregulates gene expression of endothelial nitric oxide syn-thase in human vascular endothelial cells. Circulation. 2003;107:2348–2354. doi: 10.1161/01.CIR.0000066697.19571.AF.
45. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13:34–45. doi: 10.1038/nri3345.
46. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172:2731–2738.
47. Doeing DC, Borowicz JL, Crockett ET. Gender dimorphism in differential peripheral blood leukocyte counts in mice using cardiac, tail, foot, and saphenous vein puncture methods. BMC Clin Pathol. 2003;3:3. doi: 10.1186/1472-6890-3-3.
48. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev. 1997;77:1033–1079.
49. Chu AJ, Wang ZG, Fox MJ. III. Instantaneous inhibition by compound 48/80 of tissue factor-initiated extrinsic coagulation is mediated by the downregulation of factor VII activation. Arch Biochem Biophys. 2000;377:357–365. doi: 10.1006/abbi.2000.1771.
50. Nemmar A, Hoet PH, Vermylen J, Nemery B, Hoylaerts MF. Pharmacological stabilization of mast cells abrogates late thrombotic events induced by diesel exhaust particles in hamsters. Circulation. 2004;110:1670–1677. doi: 10.1161/01.CIR.0000142053.13921.21.
51. Myers DD, Jr, Rectenwald JE, Bedard PW, Kaila N, Shaw GD, Schaub RG, Farris DM, Hawley AE, Wrobleski SK, Henke PK, Wakefield TW. Decreased venous thrombosis with an oral inhibitor of P selectin. J Vasc Surg. 2005;42:329–336. doi: 10.1016/j.jvs.2005.04.045.
52. Hamilton KK, Sims PJ. Changes in cytosolic Ca2+ associated with von Willebrand factor release in human endothelial cells exposed to histamine. study of microcarrier cell monolayers using the fluorescent probe indo-1. J Clin Invest. 1987;79:600–608. doi: 10.1172/JCI112853.
53. Hekimian G, Côte S, Van Sande J, Boeynaems JM. H2 receptor-mediated responses of aortic endothelial cells to histamine. Am J Physiol. 1992;262:H220–H224.